None
Skip to mainIndia is likely to approve Emergency Use Authorisation for the Merck drug Molnupiravir in a few days time. Molnupiravir is an oral drug designed to block the replication of various RNA viruses, including the SARS-CoV-2 virus. The medicine is meant for adults who are at risk for progressing to severe COVID-19 or hospitalization. The medicine can be taken at home.
Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR calling the drugs the "final nail in the coffin of the virus by science", said, "I think Molnupiravir will be already available to us. Five companies are sitting with the drug manufacturer... I think any day we will have approval of Molnupiravir"
Five Indian pharmaceutical companies had partnered to conduct a clinical trial of Merck (MSD)’s experimental antiviral candidate Molnupiravir to treat mild Covid-19 in an outpatient setting. The partners are Cipla, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries and Torrent Pharmaceuticals.
Molnupiravir works by disrupting the virus’s reproduction. Once the virus gets inside the body’s cells, it replicates its genome, which is made not of DNA but RNA (ribonucleic acid). These replicated genomes are then formed into complete virus particles which burst out of the cell and continue to spread around the body. However, the molecules of molnupiravir are absorbed by virus-infected cells, where they are converted into a defective version of the building blocks of RNA. So, when the virus tries to replicate, the resulting virus particles have defective genetic material and can no longer reproduce. This means that the viral load should remain low, which reduces the risk of serious disease.
In India, it might initially cost "2000 to 3000 or 4000 rupees per cycle of treatment, then it will come down to 500 to 600 or 1,000 rupees.
🕑 03 May, 2024 12:32 PM
Finance Ministry notifies LIC’s 17% wage revision
🕑 03 May, 2024 10:04 AM
Validity of CGHS empanelled Health Care Organizations (HCO’s) extended
🕑 29 Apr, 2024 09:55 PM
DoPT Clarification on increase in allowances by 25%
🕑 24 Apr, 2024 09:17 AM
DoPT forwards 8th Pay Commission demand by IRTSA forwarded to Fin Min
🕑 23 Apr, 2024 10:01 AM
CGDA: Revision of rates of Allowances with DA rates increased to 50%
🕑 22 Apr, 2024 12:59 PM
CBDT: on DoPT order on regularization of Casual Workers
🕑 21 Apr, 2024 09:54 PM
DoPT Consolidated Instructions on SC, ST, OBC, PwD & EWS reservation
🕑 18 Apr, 2024 11:51 AM
Timeline extended for CGHS Beneficiary ID - ABHA ID linking
🕑 18 Apr, 2024 10:22 AM
APAR timelines for Central Civil Services extended to 30th April
🕑 10 Apr, 2024 08:35 AM
Kendriya Vidyalaya Sangathan Admission Guidelines 2024-2025
🕑 05 Apr, 2024 01:23 PM
Kendriya Vidyalaya Balvatika Admission Schedule - 2024-25
🕑 02 Apr, 2024 09:25 AM
Kendriya Vidyalaya Admissions Open for 2024-25: Key Dates & Appln Process
🕑 01 Apr, 2024 09:23 AM
Kendriya Vidyalaya (KV) schools where Balvatika is functioning
🕑 14 Mar, 2024 02:07 PM
Govt bans 18 vulgar 18 OTT. See the list here
🕑 08 Mar, 2024 01:49 PM
Pension Scheme Gains Traction Across States, Despite Central Hurdles
🕑 20 Feb, 2024 11:17 PM
CGHS rate for general surgery applicable from February 1, 2024
🕑 08 Feb, 2024 10:19 AM
No loan interst change as RBI maintains repo rate at 6.50% for the 6th time